{"title":"Effectiveness of Nicorandil in Heart Failure: A Meta-Analysis.","authors":"Tongge Mu, Kaixuan Tang, Yan Sun","doi":"10.29271/jcpsp.2025.06.755","DOIUrl":null,"url":null,"abstract":"<p><p>This meta-analysis aims to evaluate the effectiveness of nicorandil in treating heart failure by synthesising evidence from diverse studies. The study period spanned from 12/01/2023 to 28/02/2024. Observational and randomised controlled trials have been conducted to study the cardiovascular outcomes associated with nicorandil. The findings consistently show that nicorandil, administered either intravenously or orally, significantly reduces major adverse cardiovascular events (MACEs), lowers NT-proBNP levels, and improves left ventricular ejection fraction, indicating enhanced cardiac function. Nicorandil emerges as a promising adjunctive therapy in heart failure management, potentially improving patient outcomes and decreasing the risk of MACEs. However, the exact role of this therapy in heart failure treatment requires further research. Key Words: Nicorandil, Heart failure, Major adverse cardiovascular events (MACEs), Cardiac function, Meta-analysis.</p>","PeriodicalId":94116,"journal":{"name":"Journal of the College of Physicians and Surgeons--Pakistan : JCPSP","volume":"35 6","pages":"755-760"},"PeriodicalIF":0.8000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the College of Physicians and Surgeons--Pakistan : JCPSP","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29271/jcpsp.2025.06.755","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
This meta-analysis aims to evaluate the effectiveness of nicorandil in treating heart failure by synthesising evidence from diverse studies. The study period spanned from 12/01/2023 to 28/02/2024. Observational and randomised controlled trials have been conducted to study the cardiovascular outcomes associated with nicorandil. The findings consistently show that nicorandil, administered either intravenously or orally, significantly reduces major adverse cardiovascular events (MACEs), lowers NT-proBNP levels, and improves left ventricular ejection fraction, indicating enhanced cardiac function. Nicorandil emerges as a promising adjunctive therapy in heart failure management, potentially improving patient outcomes and decreasing the risk of MACEs. However, the exact role of this therapy in heart failure treatment requires further research. Key Words: Nicorandil, Heart failure, Major adverse cardiovascular events (MACEs), Cardiac function, Meta-analysis.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
